Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A. Ascierto, Paola Queirolo, Riccardo Marconcini et al.|Journal of Translational Medicine|2014Cited by 164
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaMichele Maio, Paolo A. Ascierto, Riccardo Danielli et al.|Annals of Oncology|2013Cited by 141
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyAnna Maria Di Giacomo, Michele Maio, Paolo A. Ascierto et al.|Annals of Oncology|2014Cited by 139
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access ProgramPaolo A. Ascierto, Michele Maio, Ester Simeone et al.|Cancer Investigation|2014Cited by 105
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).Anna Maria Di Giacomo, Vanna Chiarion‐Sileni, Antonio Maria Grimaldi et al.|Journal of Clinical Oncology|2013Cited by 15